Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canadian Firm Scathing On Obstacles To Compulsory Licensing

Biolyse Is Determined To Manufacture J&J’s COVID-19 Vaccine

Executive Summary

Biolyse is seeking a compulsory license for J&J’s COVID-19 vaccine but achieving its goal is proving to be far from easy. The Canadian company argues that its experience illustrates the need for a change in approach to intellectual property rights at a local and global level.

You may also be interested in...



COVID-19 IP Waiver 'Breakthrough' At WTO Meeting

Health advocates hail the move but the EU and UK still insist a waiver is not the solution to boosting the availability of coronavirus vaccines.

EU Still Resisting COVID-19 Vaccine IP Waiver

The pharmaceutical industry and Médecins Sans Frontières have both criticized the EU’s proposals for avoiding a waiver of intellectual property rights on COVID-19 vaccines and treatments, albeit for different reasons.

EU Backs Compulsory Licensing & Production Boost For COVID-19 Vaccines

The European Commission is to present the World Health Organization with a set of proposals to tackle the barriers to the global rollout of COVID-19 vaccines. They include allowing the issue of compulsory licenses without consulting the rights holder, encouraging vaccine companies to expand production through licensing deals and contract manufacturing, and eliminating vaccine export restrictions.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel